Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Strong-Buy at Truist Financial

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by analysts at Truist Financial to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

VYGR has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $4.03 on Wednesday. The stock has a market capitalization of $240.19 million, a PE ratio of -1.99 and a beta of 1.32. The business has a 50 day simple moving average of $3.90 and a 200-day simple moving average of $4.19. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. The firm had revenue of $13.46 million for the quarter, compared to analysts’ expectations of $10.49 million. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. On average, equities research analysts anticipate that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Alfred Sandrock sold 14,197 shares of the business’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the transaction, the chief executive officer directly owned 484,060 shares in the company, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 49,783 shares of company stock valued at $188,694. 6.39% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VYGR. AQR Capital Management LLC increased its position in Voyager Therapeutics by 179.3% during the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Voyager Therapeutics in the 1st quarter valued at about $218,000. Acadian Asset Management LLC boosted its holdings in Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after buying an additional 11,929 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of Voyager Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after buying an additional 6,748 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.